GSK exceeded expectations with sales growth of 5% at CER in Q2 19, thanks to Vaccines and Consumer Health, which masked the decline in Pharmaceuticals sales. The first full quarter of Advair’s generic erosion and sluggishness in the HIV business weighed on the pharma business. The strong top-line was enough to absorb the higher cost base and was helped by lower tax to facilitate a guidance upgrade – adjusted EPS to decline by 3-5% vs the previous guidance of a 5-9% decline.
25 Jul 2019
Vaccines and consumer health mitigate pharma's weakness
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Vaccines and consumer health mitigate pharma's weakness
GSK plc (GSK:LON) | 1,598 231.7 0.9% | Mkt Cap: 66,225m
- Published:
25 Jul 2019 -
Author:
Kamla Singh -
Pages:
3
GSK exceeded expectations with sales growth of 5% at CER in Q2 19, thanks to Vaccines and Consumer Health, which masked the decline in Pharmaceuticals sales. The first full quarter of Advair’s generic erosion and sluggishness in the HIV business weighed on the pharma business. The strong top-line was enough to absorb the higher cost base and was helped by lower tax to facilitate a guidance upgrade – adjusted EPS to decline by 3-5% vs the previous guidance of a 5-9% decline.